DIFFUSE LARGE B-CELL LYMPHOMA RECURRENT

This adverse event was reported 1017 times

These drugs are most commonly taken by patients reporting DIFFUSE LARGE B-CELL LYMPHOMA RECURRENT:

# Drug Count
0 RITUXIMAB 586
1 CYCLOPHOSPHAMIDE 542
2 DOXORUBICIN 493
3 PREDNISONE 414
4 DEXAMETHASONE 232
5 DEXAMETHASONE 1.5 MG 232
6 ETOPOSIDE 226
7 CYTARABINE 190
8 DOXORUBICIN HYDROCHLORIDE 179
9 GEMCITABINE HYDROCHLORIDE 175
See all common drugs associated with DIFFUSE LARGE B-CELL LYMPHOMA RECURRENT

DIFFUSE LARGE B-CELL LYMPHOMA RECURRENT is most prevalent among patients taking these drugs:

# Drug Count Frequency
0 POLATUZUMAB VEDOTIN 107 0.0601
1 WHITE PETROLEUM 1 0.0167
2 BRINCIDOFOVIR 1 0.0127
3 IFOSFAMIDE 137 0.0104
4 DOXORUBICIN 493 0.0094
5 VINCRISTINE SULFATE 132 0.0065
6 DOXORUBICIN HYDROCHLORIDE 179 0.0063
7 ETOPOSIDE PHOSPHATE 6 0.0059
8 GEMCITABINE HYDROCHLORIDE 175 0.0055
9 CYCLOPHOSPHAMIDE 542 0.0051
See all drugs enriched for association with DIFFUSE LARGE B-CELL LYMPHOMA RECURRENT

DIFFUSE LARGE B-CELL LYMPHOMA RECURRENT is most prevalent among patients taking these drug classes:

# Drug class Count Frequency
0 Topoisomerase Inhibitor [EPC] 226 0.0048
1 Alkylating Drug [EPC] 578 0.0034
2 CD20-directed Cytolytic Antibody [EPC] 595 0.0033
3 Platinum-based Drug [EPC] 306 0.0019
4 Echinocandin Antifungal [EPC] 7 0.0015
5 Nucleoside Metabolic Inhibitor [EPC] 306 0.0015
6 Hematopoietic Stem Cell Mobilizer [EPC] 1 0.0009
7 Corticosteroid [EPC] 644 0.0007
8 Antimalarial [EPC] 4 0.0007
9 5-alpha Reductase Inhibitor [EPC] 34 0.0006
See all drug classes enriched for association with DIFFUSE LARGE B-CELL LYMPHOMA RECURRENT